Markus Munder

4PUBLICATIONS
38CO-AUTHORS
Medical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 19, 2024
Effective treatment of refractory monoclonal gammopathy-associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone.

Christian Sebastian Michel, Eva Marie Fehr, Hildegard Nolte

|Jun 16, 2024
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.

Naresh Bumma, Joshua Richter, Sundar Jagannath

|Sep 27, 2023
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.

Lisa B Leypoldt, Diana Tichy, Britta Besemer

|Nov 22, 2022
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial.

Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel

Pageof 1

Frequent Collaborators

1 joint publications

Pieter Sonneveld

1 joint publications

Ajay K Nooka

1 joint publications

Tamas Masszi

1 joint publications

Meral Beksac